Usefulness of Non TNF Usage in RA Patients

Shinshu University90 enrolled

Overview

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Sarilumab treatment for 12 months 2. Tocilizmab treatment for 12 months 3. Abatacept treatment for 12 months

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

Drug: "Salirumab"DRUG

To examine the effects of salirumab in RA patients

Drug: "Tocilizmab"DRUG

To examine the effects of tocilizmab in RA patients

Drug: "Abatacept"DRUG

To examine the effects of abatacept in RA patients

Eligibility

Sex: ALLMin age: 20 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: ・RA patients Exclusion Criteria: * Not RA patients * RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Locations (1)

Yukio Nakamura

Matsumoto, Nagano, Japan

RECRUITING

Outcomes

Primary Outcomes

Change from Baseline Values of DAS28-CRP

Assessment of efficacy in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).

Time frame: Baseline and 1 year

Assessment of adverse event in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).

Time frame: at 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.